Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (713)	11/21/2002 7:22:25 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

WE, Not to hype anything, I will said it is power of the media, one way or another. More interesting to me is that almost all analyst are neutral on Axokine. Doesn't they have priority for fresh results and/or real time consulting arrangement with investigators? So, they are: 1. Clueless what is going on 2. They know more, but keeping silence 3. None want to jump first 4. Axokine will disappoint 5. Something else BTW, it will be nice to see some positive news from VEGF-Trap. 20 and 50 mcg/kg is lowest dose for mAb targeting cancer that I have seen. Miljenko